Investors

Order intake totaling €3.32m for Q1, 2016

3 May 2016, Sophia Antipolis, France

New projects signed and major change orders on existing contracts for an amount of €1.69M. New project awards for an amount of €1.63M

MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announced today that it has recorded €3.32M of order intake for Q1, 2016. This order intake breaks down in new projects awards for an amount of €1.63M and new contracts or change orders on already existing contracts for an amount of €1.69M.

New project awards include several multiple cancer indications Phase I and Phase II studies sponsored by a major German biotech company, new client of MEDIAN Technologies.

*A project award is a notification announcing that the company’s solution has been selected for a specific project. This should result in a signed contract within 18 months, subject to upstream clinical results.

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.